195 related articles for article (PubMed ID: 30739259)
1. The predictive value of the preoperative C-reactive protein-albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data.
Xu BB; Lu J; Zheng ZF; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Lin JL; Zheng CH; Huang CM; Li P
Gastric Cancer; 2019 Sep; 22(5):1016-1028. PubMed ID: 30739259
[TBL] [Abstract][Full Text] [Related]
2. CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial.
Lu J; Xu BB; Zheng ZF; Xie JW; Wang JB; Lin JX; Chen QY; Cao LL; Lin M; Tu RH; Huang ZN; Zheng CH; Huang CM; Li P
Gastric Cancer; 2019 May; 22(3):536-545. PubMed ID: 30377862
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
4. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
5. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
6. Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.
Lu J; Xu BB; Xue Z; Xie JW; Zheng CH; Huang CM; Li P
Cancer Med; 2021 Jan; 10(1):34-44. PubMed ID: 33270989
[TBL] [Abstract][Full Text] [Related]
7. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z
Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer.
Ma M; Xiao H; Li L; Yin X; Zhou H; Quan H; Ouyang Y; Huang G; Li X; Xiao H
World J Surg Oncol; 2019 Dec; 17(1):223. PubMed ID: 31856828
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
10. The prognostic value of a Surgical Outcome Risk Tool in patients after radical gastrectomy for gastric cancer and its guiding significance for postoperative chemotherapy.
Tu RH; Lin JX; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Zheng CH; Huang CM
Surg Oncol; 2019 Mar; 28():128-134. PubMed ID: 30851886
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.
Satoh S; Okabe H; Teramukai S; Hasegawa S; Ozaki N; Ueda S; Tsuji A; Sakabayashi S; Fukushima M; Sakai Y
Gastric Cancer; 2012 Jan; 15(1):61-9. PubMed ID: 21667134
[TBL] [Abstract][Full Text] [Related]
12. Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial.
Nishikawa K; Murotani K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Hasegawa H; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2020 Jun; 132():159-167. PubMed ID: 32380427
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
14. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
18. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]